Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide.
Flawless balance sheet with proven track record.
Share Price & News
How has Arena Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RN3N has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RN3N exceeded the German Biotechs industry which returned 9% over the past year.
Return vs Market: RN3N exceeded the German Market which returned 14.4% over the past year.
Price Volatility Vs. Market
How volatile is Arena Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Arena Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RN3N's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RN3N's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RN3N is good value based on its PE Ratio (4.8x) compared to the Biotechs industry average (39.4x).
PE vs Market: RN3N is good value based on its PE Ratio (4.8x) compared to the German market (20.7x).
Price to Earnings Growth Ratio
PEG Ratio: RN3N's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: RN3N is good value based on its PB Ratio (2.4x) compared to the DE Biotechs industry average (3.6x).
How is Arena Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RN3N's earnings are forecast to decline over the next 3 years (-24.4% per year).
Earnings vs Market: RN3N's earnings are forecast to decline over the next 3 years (-24.4% per year).
High Growth Earnings: RN3N's earnings are forecast to decline over the next 3 years.
Revenue vs Market: RN3N's revenue is expected to decline over the next 3 years (-23.9% per year).
High Growth Revenue: RN3N's revenue is forecast to decline over the next 3 years (-23.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RN3N is forecast to be unprofitable in 3 years.
How has Arena Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RN3N has high quality earnings.
Growing Profit Margin: RN3N became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: RN3N has become profitable over the past 5 years, growing earnings by 63.9% per year.
Accelerating Growth: RN3N has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RN3N has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: RN3N's Return on Equity (48.4%) is considered outstanding.
Return on Assets
Return on Capital Employed
How is Arena Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: RN3N's short term assets ($806.4M) exceed its short term liabilities ($36.8M).
Long Term Liabilities: RN3N's short term assets ($806.4M) exceed its long term liabilities ($59.0M).
Debt to Equity History and Analysis
Debt Level: RN3N is debt free.
Reducing Debt: RN3N has not had any debt for past 5 years.
Debt Coverage: RN3N has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: RN3N has no debt, therefore coverage of interest payments is not a concern.
Inventory Level: RN3N has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if RN3N's debt is covered by short term assets.
What is Arena Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate RN3N's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RN3N's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RN3N's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RN3N's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RN3N's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Amit Munshi (51yo)
Mr. Amit D. Munshi has been the Chief Executive Officer and President of Arena Pharmaceuticals, Inc. since May 11, 2016. Mr. Munshi serves as Non-Executive Chairman of Enterprise Therapeutics Ltd since Mar ...
CEO Compensation Analysis
Compensation vs Market: Amit's total compensation ($USD6.86M) is above average for companies of similar size in the German market ($USD2.18M).
Compensation vs Earnings: Amit's compensation has been consistent with company performance over the past year.
|Executive VP & CFO||3.7yrs||US$3.06m||0.0069% $172.8k|
|Executive VP||18.3yrs||US$3.11m||0.019% $473.1k|
|Executive VP & Chief Business Officer||3.5yrs||US$3.16m||no data|
|Executive VP and Head of Research & Development||2.9yrs||US$3.08m||0.0080% $199.3k|
|Executive Vice President of Technical Operations||1.8yrs||no data||no data|
|Executive VP & Chief Human Resources Officer||1.5yrs||no data||no data|
|Senior VP & Chief Medical Officer||2.3yrs||no data||no data|
|Executive VP & Chief Commercial Officer||1.3yrs||no data||no data|
|Senior Vice President of Medical Affairs||1.3yrs||no data||no data|
Experienced Management: RN3N's management team is considered experienced (2.6 years average tenure).
|Independent Director||12.2yrs||US$351.61k||0.023% $578.5k|
|Independent Director||1.6yrs||US$412.63k||0.0072% $181.3k|
|Chair of the Board||3.7yrs||US$361.36k||0.023% $573.5k|
|Independent Director||3yrs||US$340.57k||0.0030% $76.1k|
|Independent Director||3yrs||US$335.33k||0.0061% $152.5k|
|Independent Director||1.2yrs||US$262.30k||0.0024% $60.9k|
|Independent Director||3yrs||US$345.57k||0.0030% $76.1k|
|Independent Director||2.7yrs||US$345.82k||0.0061% $152.5k|
Experienced Board: RN3N's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.1%.
Arena Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Arena Pharmaceuticals, Inc.
- Ticker: RN3N
- Exchange: DB
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.703b
- Listing Market Cap: US$2.504b
- Shares outstanding: 50.11m
- Website: https://www.arenapharm.com
Number of Employees
- Arena Pharmaceuticals, Inc.
- 6154 Nancy Ridge Drive
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ARNA||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 2000|
|RN3N||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2000|
|0S54||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jul 2000|
|ARNA *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jul 2000|
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn’s disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 20:39|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.